{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:23:52Z","timestamp":1770960232487,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.bpobgyn.2017.10.008","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T18:25:24Z","timestamp":1508783124000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The current place of medical therapy in uterine fibroid management"],"prefix":"10.1016","volume":"46","author":[{"given":"Jacques","family":"Donnez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Donnez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Madeleine","family":"Dolmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2017.10.008_bib1","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/humrep\/17.6.1424","article-title":"What are the implications of myomas on fertility? A need for a debate?","volume":"17","author":"Donnez","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.fertnstert.2013.03.007","article-title":"Complex networks of multiple factors in the pathogenesis of uterine leiomyoma","volume":"100","author":"Islam","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijgo.2015.04.051","article-title":"Prevalence, morbidity, and current medical management of uterine leiomyomas","volume":"131","author":"Drayer","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Updat"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.mce.2011.05.044","article-title":"The role of progesterone signaling in the pathogenesis of uterine leiomyoma","volume":"358","author":"Kim","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative invidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.fertnstert.2014.06.041","article-title":"With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?","volume":"102","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ajog.2006.02.020","article-title":"Health care resource use for uterine fibroid tumors in the United States","volume":"195","author":"Flynn","year":"2006","journal-title":"Am J Obstet Gyncol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","article-title":"The management of uterine leiomyomas","volume":"37","author":"Vilos","year":"2015","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib11","article-title":"Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 expression and regulation in uterine leiomyoma","author":"Marsh","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00441-015-2324-3","article-title":"Possible involvement of inflammatory\/reparative processes in the development of uterine fibroids","volume":"364","author":"Protic","year":"2015","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib13","doi-asserted-by":"crossref","first-page":"E601","DOI":"10.1210\/jc.2014-2134","article-title":"Human uterine leiomyoma stem\/progenitor cells expressing CD34 and CD49b initiate tumors in\u00a0vivo","volume":"100","author":"Yin","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2015.04.025","article-title":"In\u00a0vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment","volume":"104","author":"Courtoy","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib15","first-page":"4092","article-title":"Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment","volume":"83","author":"Englund","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib16","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/humrep\/14.11.2844","article-title":"Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy","volume":"14","author":"Nisolle","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.fertnstert.2015.04.024","article-title":"Increased progesterone receptor expression in uterine leiomyoma: correlation with age, number of leiomyomas, and clinical symptoms","volume":"104","author":"Tsigkou","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib18","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","article-title":"Selective progesterone receptor modulators in reproductive medicine; pharmacology, clinical efficacy and safety","volume":"96","author":"Bouchard","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/09513590.2014.950647","article-title":"Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology","volume":"30","author":"Bouchard","year":"2014","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib20","first-page":"1175","article-title":"Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications","volume":"96","author":"Chabbert-Buffet","year":"2011","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib21","first-page":"21","article-title":"The immninent dawn of SPRMs in obstetrics and gynecology","volume":"02","author":"Chabbert-Buffet","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.fertnstert.2014.07.1238","article-title":"Fibroid growth and medical options for treatment","volume":"102","author":"Chabbert-Buffet","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1586\/17446651.2014.862495","article-title":"The potential of selective progesterone receptor modulators for the treatment of uterine fibroids","volume":"9","author":"Bestel","year":"2014","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmu048","article-title":"Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications","volume":"21","author":"Moravek","year":"2015","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/GCO.0b013e32832e07e8","article-title":"Clinical utility of progesterone receptor modulators and their effect on the endometrium","volume":"21","author":"Spitz","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914 treatment for\u00a0symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib27","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.fertnstert.2013.08.039","article-title":"Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis","volume":"100","author":"Shen","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/GCO.0000000000000082","article-title":"Selective progesterone receptor modulators","volume":"26","author":"Whitaker","year":"2014","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib31","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/humrep\/det467","article-title":"Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo","volume":"29","author":"Barlow","year":"2014","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib32","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(11)61381-0","article-title":"Preoperative anaemia and postoperative outcomes in noncardiac surgery: a retrospective cohort study","volume":"378","author":"Mussalam","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130861","article-title":"Impact of preoperative anaemia and blood transfusion on postoperative outcomes in gynaecological surgery","volume":"10","author":"Richards","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptormodulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib35","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"31","author":"Williams","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1933719114549850","article-title":"The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids","volume":"22","author":"Pohl","year":"2015","journal-title":"Reprod Sci"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib37","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and Safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long-term medical management of uterine fibroids with ulipristal acetate","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/GCO.0000000000000229","article-title":"Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators","volume":"27","author":"Donnez","year":"2015","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173523","article-title":"Safety after extended repeated use of ulipristal acetate for uterine fibroids","volume":"12","author":"Fauser","year":"2017","journal-title":"Plos One"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2011.01.001","article-title":"FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. FIGO Working Group on Menstrual Disorders","volume":"113","author":"Munro","year":"2011","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib43","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/humrep\/den228","article-title":"The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology","volume":"23","author":"Engman","year":"2008","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2017.10.008_bib44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.contraception.2006.11.013","article-title":"Changes in vaginal morphology, steroid receptor and natural antimicrobial content following treatment with low-dose mifepristone","volume":"75","author":"Narvekar","year":"2007","journal-title":"Contraception"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417301712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417301712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T01:56:57Z","timestamp":1659664617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693417301712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":44,"alternative-id":["S1521693417301712"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.10.008","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current place of medical therapy in uterine fibroid management","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}